Sagimet Biosciences Inc. Series A Common Stock earnings per share and revenue
On Nov 13, 2025, SGMT reported earnings of -0.40 USD per share (EPS) for Q3 25, missing the estimate of -0.39 USD, resulting in a -1.70% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -12.24% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 12 analysts forecast an EPS of -0.43 USD, with revenue projected to reach -- USD, implying an increase of 7.50% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
What were Sagimet Biosciences Inc. Series A Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Sagimet Biosciences Inc. Series A Common Stock reported EPS of -$0.40, missing estimates by -1.7%, and revenue of $0.00, 0% as expectations.
How did the market react to Sagimet Biosciences Inc. Series A Common Stock's Q3 2025 earnings?
The stock price moved down -12.24%, changed from $8.82 before the earnings release to $7.74 the day after.
When is Sagimet Biosciences Inc. Series A Common Stock expected to report next?
The next earning report is scheduled for Mar 12, 2026.
What are the forecasts for Sagimet Biosciences Inc. Series A Common Stock's next earnings report?
Based on 12
analysts, Sagimet Biosciences Inc. Series A Common Stock is expected to report EPS of -$0.43 and revenue of -- for Q4 2025.